Data from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer

<jats:p>&lt;div&gt;Abstract Purpose:&lt;p&gt;Triple-negative breast cancer (TNBC) is a heterogeneous disease with high recurrence rates and poor prognosis, often requiring multiple therapies. BEGONIA was a phase Ib/II, multiarm, platform study evaluating the safety and efficacy of first-line treatment combinations with durvalumab (anti–PD-L1 antibody) for locally advanced, unresectable/metastatic TNBC (mTNBC; NCT03742102). In this study, we report results of 3 treatment arms.&lt;/p&gt; Patients and Methods:&lt;p&gt;Eligible female participants (≥18 years with untreated, unresectable, locally advanced/mTNBC) received durvalumab plus paclitaxel or were randomized to this treatment in combination with capivasertib (pan-AKT inhibitor) or oleclumab (anti-CD73 antibody). The primary objective was safety and tolerability; secondary endpoints included objective response rate (ORR).&lt;/p&gt; Results:&lt;p&gt;Twenty-three patients received durvalumab plus paclitaxel, 31 received capivasertib combination, and 33 received oleclumab combination. Maximum grade 3/4 adverse events occurred in 10 of 23 (43.5%), 25 of 31 (80.6%), and 8 of 33 (24.2%) patients in the durvalumab plus paclitaxel, capivasertib-combination, and oleclumab-combination arms, respectively. The confirmed ORR (95% confidence interval) was 56.5% (34.5–76.8) with durvalumab plus paclitaxel, 54.8% (36–72.7) with capivasertib combination, and 51.5% (33.5–69.2) with oleclumab combination. Responses were observed across biomarker subgroups, including PD-L1, &lt;i&gt;PIK3CA/AKT1/PTEN&lt;/i&gt; alterations, and CD73, with a trend for improved activity in the PD-L1–positive subgroups.&lt;/p&gt; Conclusions:&lt;p&gt;These findings support the clinical activity and tolerability of durvalumab plus paclitaxel in locally advanced unresectable/mTNBC, as expected for an immune checkpoint inhibitor in combination with chemotherapy. The addition of capivasertib or oleclumab to this treatment combination showed no substantial additional benefit. PD-L1 expression was associated with enhanced antitumor activity across all arms.&lt;/p&gt;&lt;/div&gt;</jats:p>